These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Computational prediction and experimental assessment of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from neutral endopeptidase. Zhang J; Jia Z; Lin Z; Li J; Fu X; Huang Y; Zhao J; Nie L; Hou W; Yuan F; Wu Y Immunol Res; 2012 Jun; 52(3):231-9. PubMed ID: 22492182 [TBL] [Abstract][Full Text] [Related]
29. A podocyte view of membranous nephropathy: from Heymann nephritis to the childhood human disease. Ronco P; Debiec H Pflugers Arch; 2017 Aug; 469(7-8):997-1005. PubMed ID: 28597189 [TBL] [Abstract][Full Text] [Related]
31. Do mesangial immune complex deposits affect the renal prognosis in membranous glomerulonephritis? Davenport A; Maciver AG; Hall CL; MacKenzie JC Clin Nephrol; 1994 May; 41(5):271-6. PubMed ID: 8050206 [TBL] [Abstract][Full Text] [Related]
32. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. Bruschi M; Carnevali ML; Murtas C; Candiano G; Petretto A; Prunotto M; Gatti R; Argentiero L; Magistroni R; Garibotto G; Scolari F; Ravani P; Gesualdo L; Allegri L; Ghiggeri GM J Proteomics; 2011 Sep; 74(10):2008-17. PubMed ID: 21640210 [TBL] [Abstract][Full Text] [Related]
33. Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men. Ronco P; Debiec H Semin Immunopathol; 2007 Nov; 29(4):445-58. PubMed ID: 17899086 [TBL] [Abstract][Full Text] [Related]
34. Differential capacity of anti-RAP and anti-megalin antibodies to produce progressive passive Heymann nephritis - implications for the pathogenesis of idiopathic human membranous glomerulonephritis. Makker SP; Tramontano A J Pathol; 2006 Nov; 210(3):282-7. PubMed ID: 16981232 [TBL] [Abstract][Full Text] [Related]
35. Detection of hepatitis C virus core protein in the glomeruli of patients with membranous glomerulonephritis. Okada K; Takishita Y; Shimomura H; Tsuji T; Miyamura T; Kuhara T; Yasutomo K; Kagami S; Kuroda Y Clin Nephrol; 1996 Feb; 45(2):71-6. PubMed ID: 8846533 [TBL] [Abstract][Full Text] [Related]
36. Antigenic targets in epimembranous glomerulonephritis. Experimental data and potential application in human pathology. Ronco P; Allegri L; Brianti E; Chatelet F; Van Leer EH; Verroust P Appl Pathol; 1989; 7(2):85-98. PubMed ID: 2567175 [TBL] [Abstract][Full Text] [Related]
37. Early-childhood membranous nephropathy due to cationic bovine serum albumin. Debiec H; Lefeu F; Kemper MJ; Niaudet P; Deschênes G; Remuzzi G; Ulinski T; Ronco P N Engl J Med; 2011 Jun; 364(22):2101-10. PubMed ID: 21631322 [TBL] [Abstract][Full Text] [Related]
38. Modulation of podocyte phenotype in collapsing glomerulopathies. Barisoni L; Kopp JB Microsc Res Tech; 2002 May; 57(4):254-62. PubMed ID: 12012394 [TBL] [Abstract][Full Text] [Related]
40. The subepithelial formation of immune complexes in membranous glomerulonephritis may be harmless and secondary to toxic or allergic factors. Ravnskov U Scand J Immunol; 1998 Nov; 48(5):469-74. PubMed ID: 9822253 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]